secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2021-09-14T23:59:59+00:00
Accession:  0001438533-21-000041
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics appoints Ruth Williams-Brinkley to Board of Directors
--------------------------------------------------------------------------

- Board expanded from 10 to 11; Ms. Williams-Brinkley elected effective Sept 14, 2021.
- Received initial grant: option for 15,750 shares and RSU for 5,250 shares, vesting over 3 years.
- Annual retainer of $50,000; subsequent annual grants of option for 9,000 shares and RSU for 3,000 shares.
- She is President of Kaiser Foundation Health Plan (Mid-Atlantic); Travere had ~$4.9M gross revenue from Kaiser (Jan 2020–Jun 2021).
- Board determined Ms. Williams-Brinkley qualifies as independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853321000041/0001438533-21-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853321000041/tvtx-20210914.htm
  HTML page:      https://secwatch.observer/filing/0001438533-21-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer